Rinvoq 30 mg 30 tablets

Product description: RINVOQ contains the active substance upadacitinib. It belongs to a group of medicines called Janus kinase inhibitors. By reducing the activity of an enzyme in the body called Janus kinase, RINVOQ decreases inflammation in the following diseases: rheumatoid arthritis, psoriasis, axial spondyloarthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis (axial spondyloarthritis), a skin condition, ulcerative colitis. Usage instructions: Always use this medicine exactly as your doctor or pharmacist has told you. Contact a doctor or pharmacist if you are not sure. How much RINVOQ to take: If you have rheumatoid arthritis, psoriasis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis): the recommended dose is one 15 mg tablet once daily. If you have atopic dermatitis: The recommended dose is 15 mg or 30 mg as per your doctor’s instructions, one tablet once daily. Your doctor may increase or decrease your dose depending on how well the medicine works. Elderly: If you are 65 years or older, the recommended dose is 15 mg once daily for long-term treatment. Adolescents (from 12 to 17 years) weighing at least 30 kg: the recommended dose is one 15 mg tablet once daily. If you have ulcerative colitis: The recommended dose is one 45 mg tablet once daily for 8 weeks. Your doctor may extend the initial 45 mg dose for another 8 weeks (for a total of 16 weeks). This is followed by one 15 mg or 30 mg tablet once daily for long-term treatment. Your doctor may increase or decrease your dose depending on how you respond to the medicine. Your doctor may reduce your dose if you have kidney problems or if other medicines have been prescribed for you. Warnings and precautions: If you are allergic to upadacitinib or any other ingredients in this medicine. If you have a serious infection (such as pneumonia or bacterial skin infection). If you have active tuberculosis. If you have serious liver problems. If you are pregnant. Components: RINVOQ 30 mg extended-release tablets: Each extended-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg of upadacitinib. Product details: Brand: RINVOQ Product model: Tablets Product type: Tablets